Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [912]
News [3692]
Articles [22]
Editorials [1]
Conferences [136]
elearning [0]
Editor's Choice for July 17
Prof Gordon McVie - Founding Editor, ecancer
Editor's Choice for July 17 ( Prof Gordon McVie - Founding Editor, ecancer )
28 Jul 2017
Celebrating a 10 year partnership: ecancer and the IEO
Prof Gordon McVie - Editor in Chief, ecancer
Celebrating a 10 year partnership: ecancer and the IEO ( Prof Gordon McVie - Editor in Chief, ecancer )
19 Jul 2017
New drugs on the horizon for pancreatic cancer
Dr Philip Philip - Karmanos Cancer Center‎, Detroit, USA
New drugs on the horizon for pancreatic cancer ( Dr Philip Philip - Karmanos Cancer Center‎, Detroit, USA )
5 Jul 2017
Latest in relapsed and refractory multiple myeloma
Prof Heinz Ludwig, Prof Wee Joo Chng and Prof James Chim
Latest in relapsed and refractory multiple myeloma ( Prof Heinz Ludwig, Prof Wee Joo Chng and Prof James Chim )
25 Jun 2017
Extended followup indicates daratumumab with bortezomib and dexamethasone for...
Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
24 Jun 2017
ZUMA1 trial of CD19 CAR T cells for aggressive NHL
Dr Yi Lin - Mayo Clinic, Rochester, USA
ZUMA1 trial of CD19 CAR T cells for aggressive NHL ( Dr Yi Lin - Mayo Clinic, Rochester, USA )
24 Jun 2017
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib
Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed...
Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017
Personalised medicine for rare cancers
Prof Paolo Casali - Università degli Studi di Milano, Milan, Italy
Personalised medicine for rare cancers ( Prof Paolo Casali - Università degli Studi di Milano, Milan, Italy )
19 Jun 2017
CAR T-cell therapy can be used to send multiple myeloma into lasting remission
Dr Wanhong Zhao - Xi’an Jiaotong University Hospital, China
CAR T-cell therapy can be used to send multiple myeloma into lasting remission ( Dr Wanhong Zhao - Xi’an Jiaotong University Hospital, China )
5 Jun 2017
Treating BRCA breast cancer with PARP inhibition
Dr Mika Sovak - AstraZeneca, Cambridge, UK
Treating BRCA breast cancer with PARP inhibition ( Dr Mika Sovak - AstraZeneca, Cambridge, UK )
4 Jun 2017
Phase III results of olaparib for BRCA breast cancer
Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA
Phase III results of olaparib for BRCA breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )
4 Jun 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation